Hemogenyx Pharmaceuticals PLC Equity Incentive Pool Increase and Option Grant (8828X)

TIDMHEMO

RNS Number : 8828X

Hemogenyx Pharmaceuticals PLC

28 April 2023

28 April 2023

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Equity Incentive Plan Pool Increase and Grant of Share Options

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that the Company's Board of Directors has resolved to increase the pool for the granting of share options, restricted shares, and restricted share units under the Company's 2021 Equity Incentive Plan with Non-Employee Sub-Plan by 60,000,000 shares, amounting to a total pool of 90,000,000 shares.

The Company has also granted a total of 57,099,966 options over ordinary shares in the capital of the Company ("Share Options") to the Company's co-founder and CEO, Dr Vladislav Sandler. The Share Options vest in two tranches of 22,839,986 Share Options ("Tranche 1") and 34,259,980 Share Options ("Tranche 2"). The Tranche 1 Share Options are being granted in recognition of Dr Sandler's work in bringing HEMO-CAR-T to the point of preparing it for submission of an Investigational New Drug ("IND") application to the US Food and Drug Administration ("FDA") for approval. The Tranche 2 Share Options will vest upon authorization by the FDA for the Company to commence clinical trials of HEMO-CAR-T.

The details of the Share Options granted are set out below:

 
 Name           Position   Number of        Exercise         Vesting Date/Criteria   Expiry Date 
                            Share Options    Price (pence) 
                            Granted 
 Dr Vladislav   CEO        22,839,986       Tranche 1:       Tranche 1:              Tranche 1: 
  Sandler                                    2.5p             immediately             27 April 
                            34,259,980       Tranche 2:                               2028 
                                             2.875p           Tranche 2:              Tranche 2: 
                                                              upon authorisation      5 years from 
                                                              by the FDA              vesting date 
                                                              to commence 
                                                              clinical trials 
                                                              of HEMO-CAR-T 
               ---------  ---------------  ---------------  ----------------------  -------------- 
 

Following the grant of the Share Options, there are, in aggregate, 92,399,552 ordinary shares of 1 penny each in the Company under option held by directors, employees and members of the Scientific Advisory Board of the Company arising from awards made under the Company's original Employee Plan, Non-Employee Plan and the 2021 Equity Incentive Plan with Non-Employee Sub-Plan. These represent 8.09% of the issued ordinary share capital of the Company.

Enquiries:

 
 Hemogenyx Pharmaceuticals plc          https://hemogenyx.com 
 Peter Redmond, Director                [e-mail] 
 
                                        Tel: [phone] 
 SP Angel Corporate Finance LLP          0470 
 Matthew Johnson, Vadim Alexandre, 
  Adam Cowl 
 
                                        Tel: [phone] 
 Peterhouse Capital Limited              0930 
 Lucy Williams, Duncan Vasey, Charles 
  Goodfellow 
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA"):

 
 1.   Details of PDMR/person closely associated with them 
 a)   Name                         Dr Vladislav Sandler 
     ---------------------------  -------------------------------------- 
 b)   Position/status              CEO, Executive Director 
     ---------------------------  -------------------------------------- 
 c)   Initial notification/        Initial notification 
       amendment 
     ---------------------------  -------------------------------------- 
 2.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of               Options over ordinary shares of 1p 
       the financial                of Hemogenyx Pharmaceuticals plc 
       instrument                   Identification code GB00BYX3WZ24 
     ---------------------------  -------------------------------------- 
 b)   Nature of the                Grant of options 
       transaction 
     ---------------------------  -------------------------------------- 
 c)   Price(s) and                  Price(s)     Volume(s) 
       volume(s)                     1. 2.5p           1. 22,839,986 
                                      2. 2.875p         2. 34,259,980 
                                                 -------------------- 
     ---------------------------  -------------------------------------- 
 d)   Aggregated information        Price(s)          Volume(s) 
       - Aggregated                  N/A - variable    57,099,966 
       volume                                         ----------- 
       - Price 
     ---------------------------  -------------------------------------- 
 e)   Date of the transaction      28/04/2023 
     ---------------------------  -------------------------------------- 
 f)   Place of the                 Outside of a trading venue 
       transaction 
     ---------------------------  -------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEKZGZDRRLGFZG

(END) Dow Jones Newswires

April 28, 2023 05:05 ET (09:05 GMT)